Search Results

IL-6 trans-signaling promotes the expansion and anti-tumor activity of CAR T cells.

• Authors : Jiang Z; Key Laboratory of Regenerative Biology South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.; Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.

Subjects: Interleukin-6/Interleukin-6/Interleukin-6/*immunology ; Receptors, Chimeric Antigen/Receptors, Chimeric Antigen/Receptors, Chimeric Antigen/*immunology ; Signal Transduction/Signal Transduction/Signal Transduction/*immunology

• Source: Leukemia [Leukemia] 2021 May; Vol. 35 (5), pp. 1380-1391. Date of Electronic Publication: 2020 Nov 09.Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium:

Record details

Metformin inhibits IL-6 signaling by decreasing IL-6R expression on multiple myeloma cells.

• Authors : Mishra AK; Division of Hematology, Mayo Clinic, Rochester, MN, 55905, USA.; Dingli D

Subjects: Gene Expression Regulation, Neoplastic*; Interleukin-6/Interleukin-6/Interleukin-6/*metabolism ; Metformin/Metformin/Metformin/*pharmacology

• Source: Leukemia [Leukemia] 2019 Nov; Vol. 33 (11), pp. 2695-2709. Date of Electronic Publication: 2019 Apr 15.Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium:

Record details

Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives

• Authors : Lonial, S.; Durie, B.; Palumbo, A.

• Source: Leukemia. March 1, 2016, p526, 10 p.

Record details

Deletion of Stat3 enhances myeloid cell expansion and increases the severity of myeloproliferative neoplasms in Jak2V617F knock-in mice

• Authors : Yan, D.; Jobe, F.; Hutchison, R.E.

• Source: Leukemia. October 1, 2015, p2050, 12 p.

Record details

Autocrine amplification of immature myeloid cells by IL-6 in multiple myeloma-infiltrated bone marrow

• Authors : Matthes, T.; Manfroi, B.; Zeller, A.

• Source: Leukemia. September 1, 2015, p1882, 9 p.

Record details

The tumor microenvironment is the main source of IL-6 for plasma cell tumor development in mice

• Authors : Rosean, T.R.; Tompkins, V.S.; Olivier, A.K.

• Source: Leukemia. January 1, 2015, p233, 5 p.

Record details

A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib

• Authors : Ray, A.; Tian, Z.; Das, D.S.

• Source: Leukemia. August 1, 2014, Vol. 28 Issue 8, p1716, 9 p.

Record details

PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis

• Authors : Berger, A.; Hoelbl-Kovacic, A.; Bourgeais, J.

• Source: Leukemia. March 1, 2014, Vol. 28 Issue 3, p629, 13 p.

Record details

The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells

• Authors : Monaghan, K.A.; Khong, T.; Burns, C.J.

• Source: Leukemia. December 1, 2011, Vol. 25 Issue 12, p1891, 9 p.

Record details

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

• Authors : Quach, H.; Ritchie, D.; Stewart, A.K.

• Source: Leukemia. Jan, 2010, Vol. 24 Issue 1, p22, 11 p.

Record details